Location Boston, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
LinkedIn View on LinkedIn
Martin Freed is a member of the board of directors for Solid Biosciences.
Martin Martin Freed brings to Solid more than 25 years of strategic development and operational expertise from across the biopharmaceutical and life sciences industries. As a seasoned drug development executive and life sciences entrepreneur, his experience spans from Phase
1 drug development through to post-registration clinical development and medical affairs programming across numerous therapeutic areas.
Martin Freed has held senior leadership positions with various biopharmaceutical companies, most recently as Co-Founder and Chief Medical Officer of Civitas Therapeutics, Inc., which was acquired by Acorda Therapeutics Inc. in 2014. Prior to Civitas, he held leadership positions at Adnexus Therapeutics, Inc., Vitae Pharmaceuticals, Inc. and SmithKline Beecham Pharmaceuticals/GlaxoSmithKline. Martin Freed has been published in more than 40 peer reviewed manuscripts, four book chapters and more than 90 abstracts related to an array of drug development and translational medicine programs. Currently, Martin Freed also holds Board positions with Dicerna Pharmaceuticals, Inc. and Sojournix, Inc.
Martin Freed performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital.
